



**Commonwealth of Massachusetts**  
**Executive Office of Health and Human Services**  
**Office of Medicaid**  
*www.mass.gov/masshealth*

**MassHealth**  
**Managed Care Organization Bulletin 6**  
**July 2016**

**TO:** Managed Care Organizations Participating in MassHealth

**FROM:** Daniel Tsai, Assistant Secretary for MassHealth

**RE: MassHealth-Contracted Managed Care Organization (MCO)  
Coverage of Hepatitis C Virus (HCV) Drugs and Other Drugs  
Subject to MassHealth Supplemental Rebate Agreements**

**Drugs Subject to MassHealth Supplemental Rebate Agreements**

There are new requirements for how MassHealth-contracted managed care organizations (MCO) may cover hepatitis C virus (HCV) drugs and other drugs subject to MassHealth supplemental rebate agreements.

Effective August 1, 2016, MCOs must do the following.

- Cover HCV Drugs for MassHealth members with no restrictions related to fibrosis score, substance use abstinence, or prescriber specialty.
- Adopt MassHealth's utilization management requirements to actively promote adherence and short courses of therapy where clinically appropriate. MCOs must report monthly to MassHealth on such utilization management activities.
- Provide coverage for HCV Drugs, as well as other drug classes, in a manner that maximizes MassHealth's ability to collect supplemental drug rebates. This includes aligning MCO drug lists with the MassHealth Drug List (including the designation of preferred HCV Drugs identified by MassHealth), not paying for HCV Drugs provided through 340B programs, and terminating any existing rebate agreements that would apply to HCV Drugs covered for MassHealth enrollees.

**Questions**

If you have any questions about the information in this bulletin, please contact the MassHealth Customer Service Center at 1-800-841-2900, e-mail your inquiry to [providersupport@mahealth.net](mailto:providersupport@mahealth.net), or fax your inquiry to 617-988-8974.